eXmoor Pharma and Siam Bioscience form strategic partnership to establish leading CGT services in Southeast Asia

Bristol, UK and Bangkok, Thailand — 23^rd September: eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Siam Bioscience, a leading biopharmaceutical company in ASEAN, today announced a strategic partnership to build the region’s foremost centre for Cell and Gene Therapy (CGT) development and manufacturing.

The collaboration aims to stimulate and accelerate the growth of the CGT industry in Thailand and Southeast Asia. It will provide a comprehensive suite of services to support local innovation and attract global therapies and investment into the region. Based in Bangkok, the new offering will serve therapy developers working to deliver advanced medicines to patients more efficiently and in full regulatory compliance.

Driving local innovation and international collaboration

Cell and gene therapies (CGTs) represent the cutting edge of biotherapeutics, functioning as one-time medicines that use genetic materials and living cells to treat various severe and rare diseases, such as cancer and genetic diseases, at a molecular or cellular level. The production of these advanced medicines involves sensitive steps, including cell harvesting, transportation, expansion, gene transduction, and infusion into the patient. Each of these steps needs to be consistent, reproducible, and traceable in order to ensure a quality of product to the patient.

Under the partnership, eXmoor will work jointly with Siam Bioscience to provide a full range of services including consultancy, process and analytical development, and GMP clinical and commercial manufacturing. These services will support CGT programmes developed in Thailand and Southeast Asia. The new centre will be located at Siam Bioscience’s manufacturing site near Bangkok, with both companies contributing their respective expertise and infrastructure to the initiative.

The partnership also aims to act as a platform to introduce international cell and gene therapies and technologies into the region. This will give patients across Southeast Asia greater access to international standard CGT, while supporting the growth of sustainable healthcare systems in the region. By offering a regionally based but globally aligned manufacturing model, the collaboration aims to reduce delays, lower logistic burdens, and improve equity of access to transformative therapies.

Angela Osborne, Executive Chair of eXmoor Pharma, commented:

“We are pleased to collaborate with Siam Bioscience on such a visionary and impactful initiative. Thailand and Southeast Asia are rapidly emerging as hubs for cell and gene therapy innovation. By combining Siam Bioscience’s regional leadership with eXmoor’s technical expertise and global CDMO capabilities, we are creating a launchpad to support both local breakthroughs and international partnerships. This is about bringing life-changing therapies to more patients, more quickly, and with the right infrastructure to support long-term success.”

Angela Osborne

Executive Chair & Founder

Songpon Deechongkit, CEC at Siam Bioscience, said:

“Partnering with eXmoor Pharma allows us to leverage its track record of supporting and growing successful CGT companies and programmes over the past 20 years to advance cell and gene therapy in our region.  Our CGT centre will not only enable access to established products, but also support translational research in Thailand and neighbouring countries, with a focus on practical commercialisation in line with international standards.  These efforts will strengthen Thailand’s position as a medical hub for the ASEAN region.”

Nualphan Lamsam, Honorary Corporate Communications Director of Siam Bioscience, said:

“As cell and gene therapies become increasingly effective in treating serious diseases such as cancer and hereditary conditions, we are truly excited about this partnership and its potential to help bring forward life-altering treatments. While Siam Bioscience has been manufacturing conventional biotech medicines for more than a decade, this collaboration takes us to the next frontier of innovation and enables us to provide both broad and niche therapies for patients in Thailand and across the region. All of these efforts align with our steadfast mission to bring better healthcare to Thai people and communities worldwide.”

About Siam Bioscience

Siam Bioscience is a leading biopharmaceutical company in ASEAN, with over 15 years of experience in research, development, manufacturing and commercialisation of biotherapeutics, vaccines and small molecules. With a state-of-the-art EU GMP-certified manufacturing facility, Siam Bioscience has successfully transferred and supplied critical technologies in collaboration with global partners. As part of its next phase of growth, the company is expanding into advanced therapeutic modalities, including cell and gene therapies, with the aim of improving access to innovative treatments across Thailand, ASEAN and neighbouring regions.

For media enquiries, please contact:

Suzanna Muggleton, IB Comms
[email protected]